Most cited papers from Humanity & Health

Humanity & Health

What are the most cited papers from Humanity & Health?

The most cited paper from Humanity & Health is "Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update" (Shiv Kumar Sarin et al., 2015), with 2,603 citations. Next come "Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma" (1,534) and "Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update" (911).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 18 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update Shiv Kumar Sarin et al. · Hepatology International Open access	13 Nov 2015	2,603
2	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma Ghassan K. Abou‐Alfa et al. · NEJM Evidence Open access	6 Jun 2022	1,534
3	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update Shiv Kumar Sarin et al. · Hepatology International Open access112 authors	6 Jun 2019	911
4	Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score Dong Ji, Dawei Zhang, Jing Xu et al. · Clinical Infectious Diseases Open access	8 Apr 2020	722
5	Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study Dong Ji, Enqiang Qin, Jing Xu et al. · Journal of Hepatology Open access	8 Apr 2020	538
6	COVID-19: Discovery, diagnostics and drug development Tarik Asselah, David Durantel, Éric Pasmant et al. · Journal of Hepatology Open access	8 Oct 2020	454
7	Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma B. Sangro et al. · Annals of Oncology Open access203 authors	19 Feb 2024	346
8	Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study) Shiv Kumar Sarin et al. · Hepatology International Open access	4 Jul 2020	296
9	Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial Vlad Ratziu et al. · Nature Medicine Open access	Oct 2021	222
10	Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents Cheng Wang, Dong Ji, Jing Chen et al. · Clinical Gastroenterology and Hepatology	5 Jul 2016	200
11	APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy George K.K. Lau et al. · Hepatology International Open access	24 Aug 2021	185
12	The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease Mohammed Eslam et al. · Hepatology International Open access	27 Feb 2025	165
13	Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta‐analysis Guofeng Chen, Cheng Wang, Jing Chen et al. · Hepatology ReviewOpen access	13 Feb 2017	164
14	Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC Lorenza Rimassa et al. · Journal of Hepatology Open access	11 Apr 2025	157
15	APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis Hong Jun You et al. · Hepatology International Open access	Feb 2022	130
16	APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation Tatsuo Kanda et al. · Hepatology International Open access	20 Sep 2019	116
17	Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection Yun‐Fan Liaw, George K.K. Lau, Jia‐Horng Kao et al. · Digestive Diseases and Sciences	17 Mar 2010	96
18	Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations APASL Covid-19 Task Force, George K.K. Lau, Manoj Sharma · Hepatology International Open access	23 May 2020	88
19	The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis Guiqiang Wang, Atsushi Tanaka, Hong Zhao et al. · Hepatology International Open access	Apr 2021	83
20	Drug-Induced Acute-on-Chronic Liver Failure in Asian Patients Harshad C. Devarbhavi et al. · The American Journal of Gastroenterology	22 Apr 2019	83
21	Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation Hongling Liu, Xi He, Yu Wang et al. · Hepatology International Open access	10 Apr 2020	80
22	Biological age estimation using circulating blood biomarkers Jordan Bortz, Andrea Guariglia, Lucija Klarić et al. · Communications Biology Open access	26 Oct 2023	75
23	Acute-on-chronic liver failure (ACLF): the ‘Kyoto Consensus’—steps from Asia Ashok Kumar Choudhury et al. · Hepatology International Open access251 authors	Feb 2025	73
24	APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 George K.K. Lau et al. · Hepatology International Open access	21 Nov 2024	71
25	Effect of COVID-19 on patients with compensated chronic liver diseases Dong Ji, Dawei Zhang, Tieniu Yang et al. · Hepatology International Open access	30 Jul 2020	69
26	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy Patrick Marcellin, Karsten Wursthorn, Heiner H. Wedemeyer et al. · Journal of Hepatology	23 Aug 2014	63
27	Ovid, Amores 15 W. S. M. Nicoll · Mnemosyne	1977	56
28	Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure Nipun Verma et al. · Hepatology International	18 Jul 2021	49
29	Safety and efficacy of eltrombopag plus pulsed dexamethasone as first‐line therapy for immune thrombocytopenia Lunqing Zhang, Mingjie Zhang, Xin Du et al. · British Journal of Haematology	13 Jan 2020	46
30	Shortening the duration of therapy for chronic hepatitis C infection Benjamin Emmanuel, Eleanor M. P. Wilson, Thomas R. OʼBrien et al. · The Lancet. Gastroenterology & hepatology Open access	9 Aug 2017	45
31	Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data Guofeng Chen et al. · PLoS ONE Open access	8 Jun 2016	44
32	Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma George K.K. Lau et al. · Journal of Hepatology Open access	30 Jul 2024	42
33	ANGPTL8 (Betatrophin) is Expressed in Visceral Adipose Tissue and Relates to Human Hepatic Steatosis in Two Independent Clinical Collectives Christian von Loeffelholz et al. · Hormone and Metabolic Research	28 Mar 2017	42
34	HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing Jennifer Audsley, Margaret Littlejohn, Lilly K. W. Yuen et al. · Virology Open access	24 Jul 2010	40
35	Antiretroviral Treatment Coverage for Men Who Have Sex With Men and Female Sex Workers Living With HIV in Cameroon Claire E. Holland, Erin Papworth, Serge Clotaire Billong et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes	27 Feb 2015	40
36	An Expert Consensus Statement on Biomarkers of Aging for Use in Intervention Studies Giorgia Perri et al. · The Journals of Gerontology Series A Open access	21 Dec 2024	39
37	Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study Dong Ji, Guo-feng Chen, Xiao-Xia Niu et al. · Metabolism Open Open access	26 Mar 2021	39
38	APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19 Shuichiro Shiina, Rino Alvani Gani, Osamu Yokosuka et al. · Hepatology International Open access	11 Nov 2020	37
39	Clinical Characteristics Predicting Progression of COVID-19 Dong Ji, Dawei Zhang, Chen Zhu et al. · SSRN Electronic Journal PreprintOpen access	2020	35
40	A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease Huai Zhang et al. · Hepatology International Open access974 authors	15 Jun 2024	34
41	Synthesis of Liver Associations Recommendations for Hepatology and Liver Transplant Care During the COVID‐19 Pandemic George K.K. Lau, John William Ward · Clinical Liver Disease Open access	May 2020	34
42	APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Tatsuo Kanda et al. · Hepatology International Open access	11 Dec 2018	32
43	Treatment of chronic hepatitis B infection‐2017 Guo‐Feng Chen, Cheng Wang, George K.K. Lau · Liver International Open access	2017	32
44	Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion George K.K. Lau · Liver International Open access	19 Jan 2010	29
45	Comparative accuracy of prognostic models for short-term mortality in acute-on-chronic liver failure patients: CAP-ACLF Nipun Verma et al. · Hepatology International	Jun 2021	28
46	Diverse Changes of Circulating Fibroblast Growth Factor 21 Levels in Hepatitis B Virus-Related Diseases Liang Wu, Qingchun Pan, Guangyu Wu et al. · Scientific Reports Open access	22 Nov 2017	28
47	APASL clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure Rakhi Maiwall et al. · Hepatology International Open access	5 Apr 2024	27
48	Impact of metabolic risk factors on the severity and outcome of patients with alcohol‐associated acute‐on‐chronic liver failure Ajay Kumar. Duseja et al. · Liver International	24 Sep 2020	26
49	947MO Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) Lorenza Rimassa, S.L. Chan, Bruno Sangro et al. · Annals of Oncology Open access	Sep 2024	25
50	‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure Ashok Kumar Choudhury et al. · Hepatology International	4 Oct 2021	25

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.